Corticosteroid responsive fludarabine pulmonary toxicity.
Fludarabine monophosphate is a purine nucleoside antimetabolite with efficacy in the treatment of lymphoproliferative disorders and chronic lymphocytic leukemia. It is the 2-fluoro, 5' phosphate derivative of 9-beta-D-arabinofuranosyl adenine (ara-A, vidarabine) and the mechanism of action is through inhibition of DNA synthesis and the cytolytic effects through the induction of endonuclease-independent apoptosis.
Stoica
George S
GS
Division of Pulmonary and Critical Care Medicine, Long Island Jewish Medical Center, New Hyde Park, New York 11042-1101, U.S.A.
Greenberg
Harly E
HE
Rossoff
Leonard J
LJ
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D001084:Vidarabine Phosphate / Q000009:adverse effects* / Q000031:analogs & derivatives; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy
D000964:Antimetabolites, Antineoplastic; D005938:Glucocorticoids; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate